About this trial
Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births.
Infants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.
Eligibility criteria
Qualifiers
all indoor newborn babies with HIE II and III
who have not received therapeutic hypothermia
Disqualifiers
grade I HIE
Babies on TH
babies whose parents do not give consent for inclusion in study
babies with major congential malformations -
Trial design
Treatments tested in this trial
- Citicoline Sodium